Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873038 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
A Phase 1 study of Kidney Failure, Chronic and Renal Dialysis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT03873038 is a Phase 1 study of Kidney Failure, Chronic and Renal Dialysis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 38 participants, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03873038, a Phase 1 study of Kidney Failure, Chronic and Renal Dialysis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MK-2060
Study Locations (3)
Florida
- Orlando Clinical Research Center ( Site 0002) - Orlando
Minnesota
- Prism Research ( Site 0003) - Saint Paul
Tennessee
- New Orleans Center for Clinical Research ( Site 0001) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2021-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03873038
The ClinicalTrials.gov registry entry for NCT03873038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (88% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03873038 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03873038 about?
NCT03873038 is a clinical study titled "Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
What is the current status of trial NCT03873038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2019-04-29. Estimated completion is 2021-12-20.
What conditions does trial NCT03873038 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, Renal Dialysis.
What interventions are being tested in trial NCT03873038?
The interventions under investigation include: Placebo (DRUG), MK-2060 (DRUG).
Who is sponsoring clinical trial NCT03873038?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03873038 being conducted?
This trial has 3 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
COMPLETED · Phase 1
-
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.